Skip to main content
Publication date
2016 05
Authors
Lipton, JH Chuah, C Guerci-Bresler, A Rosti, G Simpson, D Assouline, S Etienne, G Nicolini, FE le Coutre, P Clark, RE Stenke, L Andorsky, D Oehler, V Lustgarten, S Rivera, VM Clackson, T Haluska, FG Baccarani, M Cortes, JE Guilhot, F Hochhaus, A Hughes, T Kantarjian, HM Shah, NP Talpaz, M Deininger, MW
Group authors
EPIC Investigators
Author KI Usernames
Stenke, L|leiste
Pubmed ID
27083332
Journal
The Lancet. Oncology
Doctype
Article
KI Connection
Låg
Mesh SV
Behandlingsresultat Fusionsproteiner, bcr-abl Imatinibmesilat Imidazoler Kaplan-Meiers skattning Kombinationsterapi med cellgifter Kvinnlig Leukemi, myeloid, kronisk, BCR-ABL positiv Läkemedelsrelaterade biverkningar Manlig Medelålders personer Människa Philadelphiakromosom Pyridaziner Sjukdomsfri överlevnad Ungdomar Vuxna Äldre Äldre, 80 och över
Mesh EN
Antineoplastic Combined Chemotherapy Protocols Disease-Free Survival Drug-Related Side Effects and Adverse Reactions Fusion Proteins, bcr-abl Imatinib Mesylate Imidazoles Kaplan-Meier Estimate Leukemia, Myelogenous, Chronic, BCR-ABL Positive Philadelphia Chromosome Pyridazines Treatment Outcome
First date
2016-05-22T11:02:26.385Z